Effect of ulinastatin on expression of S100β protein and TNF-α in patients undergoing open-heart surgery with cardiopulmonary bypass

Xiu-lai ZHANG,Yi WANG,Hai-yan ZHOU,Yuan-yuan YAO,Huai-zhuang YE,Guang-min QING
DOI: https://doi.org/10.3760/j.issn:1671-0282.2007.01.013
2007-01-01
Abstract:Objective: To investigate the effect of ulinastatin on expression of S100β protein and TNF-α in patients undergoing open-heart surgery with cardiopulmonary bypass. Method: Thirty adult patients undergoing selective open-heart surgery with cardiopulmonary bypass were randomly divided into two groups (15 in each group): ulinastation (U) and control (C) group. In group U, patients received 10 000U/kg ulinastain after induction of anesthesia and before CPB. Another 10 000U/kg ulinastain was added to the priming solution at the beginning of the CPB. In group C the patients received normal saline instead of ulinastain. Blood sampleswere taken from internal jugular vein at 15 minutes after initiation of CPB (T1), at the end of CPB (T2), at 2 hours (T3) and 24 hours (T4) after the end of CPB for determination of plasma S100β protein and TNF-α levels. Results: Plasma levels of S100β protein and TNF-α in group U were significantly lower than those in group C at T2 (P < 0.01) and T3 (P < 0.05). There was no difference in both groups at T1 and T4 (P > 0.05). The plasma level of S100β protein significantly increased at T2 to T4 as compared to the baseline value at T1 in both groups (P < 0.01). In group C, TNF-α levels significantly increased at T2 and T3 as compared to the baseline value at T1 (P < 0.01). There was no significant change in the expression of TNF-α in group U (P > 0.05). Conclusions: Ulinastatin could decrease the production of TNF-α, and attenuate the expression of S100β protein in plasma.
What problem does this paper attempt to address?